InsiderTrades.com logo
JD Vance Predicts: Wall Street vs. Trump & Your Money
From Priority Gold   |   Ad
Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
Get your free guide NOW before it's too late.
Franco Valle net worth and biography
  • Phone
  • Email
  • Website

Franco Valle Biography and Net Worth

CFO of Biomea Fusion
Franco joined Biomea Fusion as Chief Financial Officer in July 2021. He brings over 16 years of progressive experience in Biotech and Pharmaceutical industry, with public and private experience. Prior to joining us, Franco was with Graphite Bio as the Senior Vice President, Finance. Previously, he held finance and leadership positions at various biotechnology companies, including Eidos Therapeutics, Inc. where he served as Senior Vice President, Finance, Iovance Biotherapeutics, Inc., as Controller, and Pharmacyclics, Inc. as Senior Director of Accounting. Franco began his career at PricewaterhouseCoopers, where he worked in the Life Science and Venture Capital Group. He received a B.S. in Corporate Finance from San Jose State University and is a Certified Public Accountant.

What is Franco Valle's net worth?

The estimated net worth of Franco Valle is at least $9,660.00 as of January 12th, 2021. Mr. Valle owns 1,500 shares of Biomea Fusion stock worth more than $9,660 as of November 23rd. This net worth estimate does not reflect any other investments that Mr. Valle may own. Additionally, Mr. Valle receives a salary of $673,660.00 as CFO at Biomea Fusion. Learn More about Franco Valle's net worth.

How old is Franco Valle?

Mr. Valle is currently 43 years old. There are 3 older executives and no younger executives at Biomea Fusion. The oldest executive at Biomea Fusion is Mr. Heow Tan, Chief Technology & Quality Officer, who is 65 years old. Learn More on Franco Valle's age.

What is Franco Valle's salary?

As the CFO of Biomea Fusion, Inc., Mr. Valle earns $673,660.00 per year. The highest earning executive at Biomea Fusion is Mr. Thomas Andrew Butler, Co-Founder, Chairman & CEO, who commands a salary of $950,410.00 per year. Learn More on Franco Valle's salary.

How do I contact Franco Valle?

The corporate mailing address for Mr. Valle and other Biomea Fusion executives is , , . Biomea Fusion can also be reached via phone at 650-980-9099 and via email at [email protected]. Learn More on Franco Valle's contact information.

Has Franco Valle been buying or selling shares of Biomea Fusion?

Franco Valle has not been actively trading shares of Biomea Fusion within the last three months. Most recently, on Friday, January 14th, Franco Valle bought 10,000 shares of Biomea Fusion stock. The stock was acquired at an average cost of $8.68 per share, with a total value of $86,800.00. Learn More on Franco Valle's trading history.

Who are Biomea Fusion's active insiders?

Biomea Fusion's insider roster includes Rainer Erdtmann (COO), and Franco Valle (CFO). Learn More on Biomea Fusion's active insiders.

Are insiders buying or selling shares of Biomea Fusion?

In the last twelve months, Biomea Fusion insiders bought shares 1 times. They purchased a total of 10,000 shares worth more than $100,600.00. The most recent insider tranaction occured on September, 30th when Director Michael J.M. Hitchcock bought 10,000 shares worth more than $100,600.00. Insiders at Biomea Fusion own 27.6% of the company. Learn More about insider trades at Biomea Fusion.

Information on this page was last updated on 9/30/2024.

Franco Valle Insider Trading History at Biomea Fusion

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/14/2022Buy10,000$8.68$86,800.00View SEC Filing Icon  
See Full Table

Franco Valle Buying and Selling Activity at Biomea Fusion

This chart shows Franco Valle's buying and selling at Biomea Fusion by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Biomea Fusion Company Overview

Biomea Fusion logo
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $6.44
Low: $6.23
High: $6.74

50 Day Range

MA: $9.40
Low: $6.28
High: $12.41

2 Week Range

Now: $6.44
Low: $3.61
High: $22.74

Volume

499,814 shs

Average Volume

823,780 shs

Market Capitalization

$233.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
JD Vance Predicts: Wall Street vs. Trump & Your Money
From Priority Gold   |   Ad
Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
Get your free guide NOW before it's too late.